PRANDIMET
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PRANDIMET (PRANDIMET).
PRANDIMET combines repaglinide (a meglitinide analog) and metformin (a biguanide). Repaglinide lowers blood glucose by stimulating insulin release from pancreatic beta cells via closure of ATP-sensitive potassium channels, leading to calcium influx and exocytosis of insulin. Metformin decreases hepatic glucose production, reduces intestinal glucose absorption, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
| Metabolism | Repaglinide is extensively metabolized by CYP2C8 and to a lesser extent by CYP3A4. Metformin is not metabolized and is excreted unchanged in urine. |
| Excretion | Renal: ~90% (60% as repaglinide metabolites, 30% as unchanged repaglinide); Biliary/fecal: ~8% |
| Half-life | Terminal elimination half-life: 1-1.5 hours. Clinically, repaglinide has a short half-life, allowing for flexible dosing immediately before meals. |
| Protein binding | >98% bound, primarily to albumin. |
| Volume of Distribution | Vd: approximately 0.15 L/kg, indicating binding to tissues; not widely distributed. |
| Bioavailability | Oral: 56% (absolute bioavailability due to first-pass metabolism). |
| Onset of Action | Oral: 15-30 minutes; peak plasma concentration at 1 hour. |
| Duration of Action | Duration: 2-4 hours. Clinical notes: Short duration reduces risk of late postprandial hypoglycemia; should be taken before meals. |
Initial dose: 1.25 mg repaglinide/250 mg metformin orally twice daily with meals. Maximum dose: 10 mg repaglinide/2500 mg metformin per day.
| Dosage form | TABLET |
| Renal impairment | Contraindicated if eGFR < 30 mL/min/1.73 m². If eGFR 30-44 mL/min/1.73 m², reduce metformin component to 500 mg twice daily and monitor renal function. Discontinue if eGFR falls below 30. |
| Liver impairment | Contraindicated in patients with Child-Pugh class C cirrhosis. For Child-Pugh class A or B, use with caution; avoid repaglinide if severe hepatic impairment. |
| Pediatric use | Safety and efficacy not established in pediatric patients. No recommended dose. |
| Geriatric use | Start at lowest dose (0.5 mg repaglinide/250 mg metformin) due to increased risk of hypoglycemia and renal impairment. Titrate slowly and monitor renal function closely. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for PRANDIMET (PRANDIMET).
| Breastfeeding | Metformin is excreted into breast milk in low amounts (M/P ratio ~0.35); glipizide excretion is negligible. Compatible with breastfeeding, but monitor infant for hypoglycemia. The American Academy of Pediatrics considers metformin compatible; glipizide has limited data. |
| Teratogenic Risk | FDA Pregnancy Category C. First trimester: Potential risk based on animal data showing fetal toxicity; no adequate human studies. Second and third trimesters: Use only if benefit outweighs risk; may cause neonatal hypoglycemia and electrolyte abnormalities due to placental transfer of metformin and glipizide. Avoid near term due to prolonged neonatal hypoglycemia risk from sulfonylurea. |
■ FDA Black Box Warning
Lactic acidosis: Metformin can cause lactic acidosis, a rare but serious complication (mortality >50%). Risk factors include renal impairment, concomitant use of contrast media, hypoxia, sepsis, excessive alcohol intake, hepatic impairment, and acute heart failure. Discontinue metformin if lactic acidosis is suspected.
| Serious Effects |
["Hypersensitivity to repaglinide, metformin, or any component","Diabetic ketoacidosis with or without coma","Type 1 diabetes mellitus","Renal impairment: eGFR <30 mL/min/1.73 m²","Acute or chronic metabolic acidosis","Lactic acidosis","Severe hepatic impairment","Concomitant use with gemfibrozil"]
| Precautions | ["Lactic acidosis risk with metformin","Hypoglycemia risk with repaglinide","Cardiovascular effects: repaglinide may increase cardiovascular mortality (though not confirmed)","Hypersensitivity reactions","Renal impairment: metformin contraindicated if eGFR <30 mL/min/1.73 m²; use with caution if eGFR 30-45 mL/min/1.73 m²","Hepatic impairment","Alcohol intake","Surgery and radiologic studies with iodinated contrast","Concomitant use with insulin secretagogues or insulin","Fever, trauma, infection, or surgery may cause temporary loss of glycemic control"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood glucose and HbA1c throughout pregnancy. Assess fetal growth and amniotic fluid volume via ultrasound due to potential macrosomia. Monitor neonatal blood glucose for 24-48 hours postpartum for hypoglycemia. Check renal function and electrolyte levels in mother. |
| Fertility Effects | Metformin may improve ovulation in women with PCOS, potentially increasing fertility. No known adverse effects on fertility with glipizide. In males, no significant impact reported. |